Casdin Capital LLC Sells 26,500 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Casdin Capital LLC lessened its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 32.5% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 55,000 shares of the biopharmaceutical company’s stock after selling 26,500 shares during the period. Alnylam Pharmaceuticals makes up 2.1% of Casdin Capital LLC’s holdings, making the stock its 10th largest position. Casdin Capital LLC’s holdings in Alnylam Pharmaceuticals were worth $25,080,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of ALNY. OFI Invest Asset Management boosted its stake in Alnylam Pharmaceuticals by 5.8% during the third quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 22 shares in the last quarter. Howard Capital Management Inc. raised its position in Alnylam Pharmaceuticals by 2.9% in the third quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company’s stock worth $389,000 after acquiring an additional 24 shares in the last quarter. Frank Rimerman Advisors LLC raised its position in Alnylam Pharmaceuticals by 2.0% in the third quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company’s stock worth $570,000 after acquiring an additional 24 shares in the last quarter. Coastal Bridge Advisors LLC lifted its holdings in Alnylam Pharmaceuticals by 2.3% in the 3rd quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company’s stock valued at $500,000 after acquiring an additional 25 shares during the last quarter. Finally, Meridian Financial Advisors LLC boosted its position in shares of Alnylam Pharmaceuticals by 3.5% during the 3rd quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock valued at $378,000 after purchasing an additional 28 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,598 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total transaction of $523,584.70. Following the transaction, the executive vice president directly owned 36,606 shares of the company’s stock, valued at approximately $11,993,955.90. The trade was a 4.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $319.73, for a total transaction of $528,193.96. Following the completion of the transaction, the executive vice president owned 21,860 shares in the company, valued at approximately $6,989,297.80. This represents a 7.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 53,923 shares of company stock valued at $18,072,087 in the last 90 days. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 1.2%

Shares of Alnylam Pharmaceuticals stock opened at $313.41 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The company has a market cap of $41.56 billion, a P/E ratio of 183.28 and a beta of 0.36. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The stock has a 50-day moving average price of $344.35 and a 200 day moving average price of $409.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.18). The business had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company’s revenue was up 84.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.65) EPS. As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Freedom Capital raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 17th. Canaccord Genuity Group increased their target price on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday, January 15th. Bank of America restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. Finally, Royal Bank Of Canada dropped their price target on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating on the stock in a report on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $477.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.